This company has already tried the gofundme route with specials. That isn't commercially viable. UK is also notoriously tight with their national reimbursement. And they haven't even started on MHRA reumbusement which is incredulous at this point. But everyone except LP and her paid pumps know this. There is no path to revenue......that is the bottomline and that means endless share daily dilution with or without r/s.
You are likely going to see what happens when political pressure hits regarding access to funding from IFRs for a product designed to treat cancer as its indication that has already been approved . A 5 doctor panel review team is going to have its hands full trying to keep up and I expect there will be some very quick expedited reviews in some cases or that team will look really bad as will those who put it all on that team without preparing for coming demand from a potential breakthrough therapy. I would guess that those members of parliament (MPs) who know where to put the pressure and are able to speak preemptively to the issue of access are probably looking at this right now to bring up as a potential issue already. Best wishes.
Market Data 
Markets 
AI
